Posology : מינונים

4.2   Posology and method of administration
Posology
The recommended dose of Zomig to treat a migraine attack is 2.5 mg.
If symptoms persist or return within 24 hours, a second dose has been shown to be effective. If a second dose is required, it should not be taken within 2 hours of the initial dose.
If a patient does not achieve satisfactory relief with 2.5 mg doses, subsequent attacks can be treated with 5 mg doses of Zomig.
In those patients who respond, significant efficacy is apparent within 1 hour of dosing.
Zomig is equally effective whenever the tablets are taken during a migraine attack; although it is advisable that Zomig is taken as early as possible after the onset of migraine headache.
In the event of recurrent attacks, it is recommended that the total intake of Zomig in a       24 hour period should not exceed 10 mg.
Zomig is not indicated for prophylaxis of migraine.


Paediatric population (under 12 years of age)
The safety and efficacy of Zomig tablets in children aged 0-12 years has not yet been established. No data are available. Use of Zomig in children is therefore not recommended.
Adolescents (12 - 17 years of age)
The efficacy of Zomig tablets was not demonstrated in a placebo controlled clinical trial for patients aged 12 to 17 years. Use of Zomig tablets in adolescents is therefore not recommended.
Elderly
Safety and efficacy of Zomig in individuals aged over 65 years have not been systematically evaluated.
Hepatic impairment
Metabolism is reduced in patients with hepatic impairment (see Section 5.2).
Therefore for patients with moderate or severe hepatic impairment a maximum dose of 5 mg in 24 hours is recommended.
Renal impairment
No dosage adjustment required (see Section 5.2).

Method of administration
To be taken by oral administration.